Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Codeine,Metamizole
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 22, 2021
Lead Product(s) : Codeine,Metamizole
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Caffeine,Isometheptene Mucate,Metamizole
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Hypera Pharma
Deal Size : $825.0 million
Deal Type : Divestment
Takeda Completes Sale of Select OTC and Non-Core Assets to Hypera Pharma
Details : The divested portfolio includes select over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, and other South American, Central American and Caribbean countries, which are part of Takeda’s Growth & Emerging Markets Business U...
Product Name : Neosaldina
Product Type : Dietary Supplement
Upfront Cash : Undisclosed
January 29, 2021
Lead Product(s) : Caffeine,Isometheptene Mucate,Metamizole
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Hypera Pharma
Deal Size : $825.0 million
Deal Type : Divestment
Lead Product(s) : Caffeine,Isometheptene Mucate,Metamizole
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Hypera Pharma
Deal Size : $825.0 million
Deal Type : Divestment
Details : The portfolio includes over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru, which are part of Takeda’s Business Unit.
Product Name : Neosaldina
Product Type : Dietary Supplement
Upfront Cash : Undisclosed
February 03, 2020
Lead Product(s) : Caffeine,Isometheptene Mucate,Metamizole
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Hypera Pharma
Deal Size : $825.0 million
Deal Type : Divestment
Lead Product(s) : Dihydroergotamine Mesylate,Metamizole,Caffeine
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 11, 2016
Lead Product(s) : Dihydroergotamine Mesylate,Metamizole,Caffeine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibuprofen,Metamizole,Paracetamol
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ibuprofen, Acetaminophen and Dipyrone to Fever Control in Children
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2011
Lead Product(s) : Ibuprofen,Metamizole,Paracetamol
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable